Boston Scientific profit gains as electrophysiology sales drive double-digit growth
Boston Scientific (NYSE:BSX) reported fourth-quarter results that topped analyst estimates, driven by a double-digit surge in its cardiovascular division and a string of regulatory wins that are reshaping its competitive landscape.







-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)
